Core Viewpoint - FibroBiologics, Inc. has announced a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, along with a concurrent private placement of unregistered warrants for the same number of shares at the same exercise price, aiming to raise approximately $1.5 million in gross proceeds [1][3]. Group 1: Offering Details - The offering consists of 4,477,614 shares of common stock priced at $0.335 each, with a concurrent issuance of unregistered warrants to purchase the same number of shares at the same price [1]. - The closing of the offering is expected around November 25, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 2: Financial Implications - The total gross proceeds from the offering are anticipated to be approximately $1.5 million before deducting fees and expenses [3]. - If the unregistered warrants are fully exercised, an additional gross proceeds of approximately $1.5 million could be realized [3]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The shares are being offered under a "shelf" registration statement on Form S-3, which became effective on February 10, 2025 [4]. - The unregistered warrants and shares from the private placement are offered under Section 4(a)(2) of the Securities Act and have not been registered [5]. Group 4: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [9]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer, representing advancements in cell therapy and tissue regeneration [9].

Core Insights - Digerati Technologies has successfully acquired Ricochet Global, enhancing its capabilities in telecommunications services, particularly in Africa, the Middle East, and the Persian Gulf [1][2]. Company Overview - Digerati Technologies operates as a holding company and provides co-location and technology infrastructure solutions through its subsidiary, WaivCloud, Inc. [4]. - WaivCloud focuses on delivering secure, reliable, and scalable data center solutions, emphasizing exceptional customer service and personalized support [4]. Acquisition Details - The acquisition of Ricochet was executed through a combination of cash and restricted common stock [2]. - Ricochet is recognized for its advanced switching and routing architecture, which ensures high-quality service while maintaining efficiency [2]. Leadership Statements - Jason Mumper, Founder of Ricochet, expressed enthusiasm about joining Digerati and aims to leverage the acquisition to create significant value [3]. - Robert Delvecchio, Chairman and CEO of Digerati, highlighted the acquisition as a pivotal moment for the company, aiming to utilize Ricochet as a foundational platform for future growth and additional acquisitions [3].

Core Viewpoint - The preliminary valuation of the Baltic Horizon Fund's portfolio indicates a decrease in fair value to EUR 208.7 million from EUR 228.3 million as reported in the interim financial statements as of 30 September 2025 [1]. Group 1 - The fund manager is in the process of finalizing the review of valuation models and will report the final effects along with the NAV of the Fund for the end of November 2025 [2]. - A summary of property valuations will be published on the Fund's webpage following the final report [2].

Core Insights - FEI-Zyfer, Inc. has received two follow-on change orders valued at approximately $4.75 million for the development and manufacture of high-precision airborne time, synchronization, and frequency distribution systems, with deliveries scheduled through 2027 [1] - The airborne-rated systems are designed to operate in high-dynamic environments and are compatible with the latest Assured-Position, Navigation and Timing (A-PNT) and Alternative (Alt-PNT) avionics, supporting collaborative airborne operations [1] - The company emphasizes its investment in developing a revolutionary Rubidium Atomic Clock optimized for demanding airborne applications, claiming unmatched performance in the field-deployable atomic clock market [2] Company Overview - Frequency Electronics, Inc. is a leader in high precision timing, frequency generation, and RF control products for both space and terrestrial applications, serving various sectors including military and commercial systems [3] - The company has received over 100 awards for excellence in providing high-performance electronic assemblies for more than 150 space and Department of Defense programs, highlighting its commitment to research and development [3] - FEI's mission is to transform laboratory discoveries into practical products, focusing on precision time and frequency generation for critical applications [3]

Core Viewpoint - Connect Biopharma Holdings Limited is participating in the 8th Annual Evercore Healthcare Conference, highlighting its focus on transforming care for inflammatory diseases, particularly asthma and COPD [1][3]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing rademikibart, an antibody targeting IL-4Rα for asthma and COPD treatment [3]. - The company is conducting global clinical studies for rademikibart, addressing significant unmet needs in acute exacerbations of asthma and COPD [3]. - Connect Biopharma has granted an exclusive license for rademikibart to Simcere Pharmaceutical Co., Ltd. in Greater China, with potential milestone payments up to approximately $110 million and tiered royalties on net sales [3]. Event Participation - Company management will engage in a fireside chat at the conference on December 2, 2025, at 10:50 a.m. ET, with a live webcast available on the company's investor website [1][2].

Core Insights - Chaince Digital Holdings Inc. has entered a non-binding Strategic Cooperation Framework Agreement with ZJK Industrial Co., Ltd. to establish a precision components R&D and manufacturing gigafactory in the U.S. aimed at serving the AI and semiconductor industries [1][2] Investment and Financial Commitment - The companies plan to invest up to $200 million through various projects, utilizing both self-owned capital and external fundraising to strengthen the U.S. high-end manufacturing ecosystem [2] Gigafactory Focus and Operations - The gigafactory will concentrate on high-value, non-restricted precision components across multiple technology categories, excluding restricted semiconductor segments like wafer fabrication and chip design [3] - A Delaware joint venture will be formed to operate the gigafactory, overseeing all operations from R&D to full-scale production [5] Competitive Advantages and Management - The collaboration aims to enhance the made-in-America vision by combining ZJK's manufacturing expertise with Chaince Digital's strengths in capital markets and digital technologies [6] - The joint venture will feature a U.S.-based management team with executives from leading American companies, targeting key industries such as AI hardware and electric vehicles [6] Product Focus - The gigafactory will produce components for AI end-devices, semiconductor equipment, liquid-cooling systems, new energy vehicles, smart wearables, and other consumer electronics [7] Strategic Advisory Role - Chaince Securities has been appointed as ZJK's capital markets strategic advisor for five years, focusing on capital markets strategy and financing needs [4][8] Leadership Statements - ZJK's CEO emphasized that the partnership will enhance their manufacturing footprint in the U.S. and support the Made in America initiative [9] - Chaince Digital's Chief Strategy Officer expressed commitment to leveraging their strengths to support the gigafactory's development [9]

New members include former officials from the U.S. Department of Energy, Federal Bureau of Investigation, and U.S. Marine CorpsSANTA CLARA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Netskope, (NASDAQ: NTSK) a leader in modern security and networking for the cloud and AI era, today announced the addition of three veteran United States federal government leaders to its U.S. Federal Advisory Board. These experienced executives will provide strategic guidance on Netskope’s go-to-market strategy and efforts in U ...

Core Insights - Figure Technology Solutions has announced a $25 million strategic investment from Ondo Finance in its $YLDS stablecoin, enhancing the yield source for Ondo's flagship tokenized fund, OUSG [1][2][3] - The partnership aims to strengthen the position of $YLDS in the tokenized real-world assets market and accelerate institutional adoption of on-chain finance [3][5] Company Overview - Figure Technology Solutions operates a blockchain-based capital marketplace, having originated over $19 billion in home equity financing, making it the largest non-bank provider in this sector [4][5] - The company’s ecosystem includes various components such as Figure Connect, a consumer credit marketplace, and Democratized Prime, an on-chain lending platform [4] Product Details - $YLDS is a registered security that pays interest to holders and is backed by the same assets as GENIUS Act stablecoins, providing a unique utility in the market [2][4] - The integration of $YLDS into OUSG's yield strategy is expected to diversify and institutionalize the ecosystem supporting Ondo's products [3][4] Strategic Importance - The investment from Ondo Finance is seen as a natural connection due to both companies' strong presence in tokenized Real-World Assets (RWAs) [2][3] - This collaboration is positioned to enhance Figure's expansion efforts, particularly around its DeFi platform, Democratized Prime [2][3]

Core Insights - Stereotaxis is participating in the Piper Sandler 37th Annual Healthcare Conference, with CEO David Fischel scheduled for a discussion and one-on-one meetings on December 3, 2025 [1][2] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, focusing on the development of robotic systems and solutions that enhance patient care and operational efficiency [2] - The company's technology has been utilized to treat over 150,000 patients globally, indicating a significant market presence [2]

Core Insights - OneMedNet Corporation has received strong validation for its redesigned data exploration and cohort-building platform from customers and prospects at ISPOR Europe, showcasing its commercial relevance and competitive differentiation [2][3] - The platform, built on Palantir Foundry and AIP, allows research teams to determine cohort feasibility in minutes instead of weeks, enhancing accuracy and efficiency [3][4] Company Overview - OneMedNet operates the largest global live, regulatory-grade AI-ready Real-World Data (RWD) network, encompassing over 2,130 provider sites, 47+ million unique patient lives, and 186+ million clinical exams and images [2][4] - The company aims to revolutionize the use of Real-World Data, providing insights that drive innovation in drug development, medical devices, and AI applications [4][5] Technological Advancements - Key advancements of the new platform include significantly faster cohort feasibility, AI-driven natural-language search for complex discovery tasks, and real-time availability of longitudinal insights [7] - The platform supports subscription workflows, which is expected to contribute to recurring-revenue growth for the company [7]